Real‐world persistence and dose titration of GLP ‐1 receptor agonists in type 2 diabetes: A UK population‐based cohort study by obesity and cardiovascular disease status

Documenti analoghi

• Real‐world treatment trajectories preceding GLP ‐1 receptor agonist initiation in type 2 diabetes: A descriptive UK population‐based cohort study on adherence to national clinical guidelines
  di: Franziska S. Ulrich, et al.
  Pubblicazione: (2026)
• GLP ‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity
  di: Tommaso Bucci, et al.
  Pubblicazione: (2025)
• Beyond diabetes and obesity: GLP ‐1 receptor agonists in disrupting the vicious cycle of metabolic dysfunction and neuroinflammation
  di: Renata Spezani, et al.
  Pubblicazione: (2025)
• Real‐world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic
  di: Jason M. Samuels, et al.
  Pubblicazione: (2025)
• Effectiveness and safety of GLP ‐1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real‐world study
  di: Flora Lambert, et al.
  Pubblicazione: (2025)